Operating margin · 2024–2025
Monte Rosa Therapeutics operating margin
−43.8%+63.4 pp · FY2025
Monte Rosa Therapeutics (GLUE) reported −43.8% in operating margin for fiscal 2025, +63.4 pp from the year before.
| Fiscal year | Operating margin | Change | Filing |
|---|---|---|---|
| FY2025 | −43.8% | +63.4 pp | Derived |
| FY2024 | −107.3% | — | Derived |
Operating margin — Operating margin is operating income divided by revenue. Only companies with at least $1 billion in revenue are ranked here.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026
Calculated from two reported figures, so it has no single filing of its own.
Operating margin at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Monte Rosa Therapeutics operating margin |url=https://companiesranked.com/en/company/monte-rosa-therapeutics/operating-margin |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Monte Rosa Therapeutics operating margin. CompaniesRanked. https://companiesranked.com/en/company/monte-rosa-therapeutics/operating-marginBibTeX
@misc{companiesranked-en-company-monte-rosa-therapeutics-operating-margin-2026,
author = {{CompaniesRanked}},
title = {{Monte Rosa Therapeutics operating margin}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/monte-rosa-therapeutics/operating-margin}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.